| Elinogrel | acute coronary syndrome, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | Non fatal MI | 1.06 [0.02 54.90] | p=1.00 | 0 | 70 | 1 | ERASE-MI, | | non cardiovascular death | no data | | Non fatal stroke | 3.18 [0.12 80.77] | p=1.00 | 0 | 70 | 1 | ERASE-MI, | | Major bleeding | 1.06 [0.02 54.90] | p=1.00 | 0 | 70 | 1 | ERASE-MI, |
| Trial | Studied treatment | Control | Patients |
|---|
| ERASE-MI, 2009 | elinogrel 10, 20, 40, or 60 mg as a single intravenous bolus | placebo | STEMI patients |
| |
| Ticagrelor | acute coronary syndrome, in all type of patients | vs clopidogrel | all cause death, MI, stroke by 16% suggested cardiovascular events by 15% suggested myocardial infarction (fatal and non fatal) by 16% suggested Vascular death by 20% suggested All cause death by 21% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | 0.84 [0.77 0.92] | p=0.04 | 0 | 18624 | 1 | PLATO, | | refractory ischemia | no data | | cardiovascular events | 0.85 [0.78 0.94] | p=0.04 | 0 | 19285 | 2 | PLATO, DISPERSE-2 (90mg), | | myocardial infarction (fatal and non fatal) | 0.84 [0.75 0.95] | p=0.04 | 0 | 19285 | 2 | PLATO, DISPERSE-2 (90mg), | | stroke (fatal and non fatal) | 1.18 [0.91 1.53] | p=1.00 | 0 | 19285 | 2 | PLATO, DISPERSE-2 (90mg), | | ischemic stroke | 1.05 [0.79 1.40] | p=1.00 | 0 | 18624 | 1 | PLATO, | | Vascular death | 0.80 [0.70 0.92] | p=0.04 | 0 | 19285 | 2 | PLATO, DISPERSE-2 (90mg), | | Non vascular death | 0.72 [0.49 1.05] | p=1.00 | 0 | 18624 | 1 | PLATO, | | Non fatal MI | no data | | Revascularization | no data | | All cause death | 0.79 [0.69 0.90] | p=0.04 | 0 | 19285 | 2 | PLATO, DISPERSE-2 (90mg), | | Non fatal stroke | no data | | fatal bleeding | 0.87 [0.48 1.58] | p=1.00 | 0 | 18624 | 1 | PLATO, | | Bleeding | 1.04 [0.95 1.14] | p=1.00 | 0 | 19285 | 2 | PLATO, DISPERSE-2 (90mg), | | Major bleeding | 1.02 [0.92 1.14] | p=1.00 | 0 | 19285 | 2 | PLATO, DISPERSE-2 (90mg), |
| Trial | Studied treatment | Control | Patients |
|---|
| PLATO, 2009 | ticagrelor 90mg twice daily | clopidogrel 75mg once daily | patients with an acute coronary syndrome, with or without
ST-segment elevation (onset
of symptoms within the previous 24h). | | DISPERSE-2 (90mg), 2007 | ticagrelor 90 mg twice daily | clopidogrel | patients with NSTE-ACS, treated with aspirin and standard therapy for ACS |
| |
| Cangrelor | acute coronary syndrome, in all type of patients | vs clopidogrel up front | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 1.04 [0.88 1.24] | p=1.00 | 0 | 7754 | 1 | CHAMPION-PCI, | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.40 [0.12 1.27] | p=1.00 | 0 | 7754 | 1 | CHAMPION-PCI, | | stroke (fatal and non fatal) | 0.85 [0.29 2.54] | p=1.00 | 0 | 7754 | 1 | CHAMPION-PCI, | | MACE | 0.67 [0.40 1.14] | p=1.00 | 0 | 7754 | 1 | CHAMPION-PCI, | | All cause death | 1.59 [0.52 4.87] | p=1.00 | 0 | 7754 | 1 | CHAMPION-PCI, | | Major bleeding | no data | | net benefit | no data | | stent thrombosis | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| CHAMPION-PCI, 2009 | cangrelor up front (cangrelor administered before percutaneous coronary intervention and followed by clopidogrel) | clopidogrel up front (clopidogrel followed by placebo) | high risk patients requiring PCI |
| |
| Cangrelor | | vs delayed clopidogrel | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.87 [0.71 1.07] | p=1.00 | 0 | 5355 | 1 | CHAMPION-PLATFORM, | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.91 [0.74 1.13] | p=1.00 | 0 | 5355 | 1 | CHAMPION-PLATFORM, | | stroke (fatal and non fatal) | 1.15 [0.39 3.44] | p=1.00 | 0 | 5355 | 1 | CHAMPION-PLATFORM, | | MACE | no data | | All cause death | no data | | Major bleeding | no data | | net benefit | no data | | stent thrombosis | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| CHAMPION-PLATFORM, 2009 | cangrelor up front (cangrelor during PCI followed by 600 mg of clopidogrel) | delayed clopidogrel (placebo during PCI followed by 600 mg of clopidogrel) | patients with acute coronary syndrome undergoing percutaneous coronary intervention |
| |
| Prasugrel | acute coronary syndrome, in all type of patients | vs clopidogrel | fatal bleeding by 319% adverse event Bleeding by 31% adverse event Major bleeding by 31% adverse event Non fatal MI by 24% suggested Revascularization by 33% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | ischemic stroke | no data | | Vascular death | 0.88 [0.70 1.12] | p=1.00 | 0 | 13608 | 1 | TRITON-TIMI 38, | | Non fatal MI | 0.76 [0.67 0.87] | p=0.04 | 0 | 13608 | 1 | TRITON-TIMI 38, | | Revascularization | 0.67 [0.54 0.82] | p=0.04 | 0 | 13608 | 1 | TRITON-TIMI 38, | | All cause death | 0.95 [0.78 1.17] | p=1.00 | 0 | 13608 | 1 | TRITON-TIMI 38, | | Non fatal stroke | 1.01 [0.71 1.45] | p=1.00 | 0 | 13608 | 1 | TRITON-TIMI 38, | | fatal bleeding | 4.19 [1.58 11.12] | p=0.04 | 0 | 13608 | 1 | TRITON-TIMI 38, | | Bleeding | 1.31 [1.10 1.56] | p=0.04 | 0 | 13608 | 1 | TRITON-TIMI 38, | | Major bleeding | 1.31 [1.02 1.68] | p=0.04 | 0 | 13608 | 1 | TRITON-TIMI 38, |
| Trial | Studied treatment | Control | Patients |
|---|
| JUMBO-TIMI 26, 2005 | Prasugrel 3 doses | clopidogrel 300mg loading dose
followed by 75 mg daily) | patients undergoing elective or urgent percutaneous coronary intervention | | TRITON-TIMI 38, 2007 | prasugrel 60-mg loading dose
and 10-mg daily maintenance dose, for 6 to 15 months | clopidogrel (a 300-mg loading dose and a
75-mg daily maintenance dose) for 6 to 15 months | patients with moderate-to-high-risk acute coronary syndromes (UA, NSTEMI,STEMI) with scheduled
percutaneous coronary intervention |
| |
